This post highlights the top three most viewed videos related to stem cell research on YouTube. These videos were all released within the last five years, and provide different, innovative angles on how stem cell research is revolutionizing our world today.
BioInformant is proud and honored to be a sponsor for the upcoming “Perinatal Stem Cell Society Conference” in Aspen, Colorado, over March 2-4, 2016. This 3-day event will feature the world’s leading perinatal stem cell researchers, specializing in Amnion, Amniotic fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. BioInformant’s sponsorship of the event is in collaboration with Save the Cord Foundation, as part of our partnership to promote cord blood banking awareness around the world.
The Perinatal Stem Cell Society was founded on the basic principle that stem cells from perinatal tissues contain enormous, untapped life potential to treat many disorders. It will be hosting a scientific program with topics covering all aspects of the perinatal stem cell field. Attendees are actively advancing perinatal stem cell research, and focused on paths towards treatment. Continue reading BioInformant is Proud Sponsor for the Perinatal Stem Cell Society Conference
Cellular Dynamics International Announces Launch of CIRM hPSC Repository and First 300 iPSC Lines
Cellular Dynamics International (CDI), a FUJIFILM company since March of 2015, announced news today that has reverberated throughout the stem cell community, suggesting hope and progress for the future of stem cell research.
As an indisputable leader in the the manufacture and production of iPS cell products, Cellular Dynamics was awarded a $16 million grant by the California Institute of Regenerative Medicine in March of 2013. In that landmark funding awarded, CIRM allocated $16 million for CDI to create 3 induced pluripotent stem cell (iPSC) lines from 3000 healthy and diseased donors. At the same time, CIRM awarded Coriell Institute approximately $10 million to structure and store the iPSC lines within a secure biobanking facility, of which CDI was to be a “primary subcontractor.” Continue reading CDI, a FUJIFILM company, Announces Launch of World’s Largest Public Stem Cell Bank
Little Known Evolution of Cord Blood Industry Advocacy
The global cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the United States, followed by the establishment of cord blood banks in other regions across the globe. However, the history of cord blood stem cell transplants actually began nearly a decade prior to that.
Since iPSCs were first produced in 2006 from mouse cells and in 2007 from human cells, scientists have recognized the incredible potential of the cell type, including their utility in drug and toxicology screening, disease modeling, and cellular therapy applications ranging from gene correction, to whole tissue regeneration, individualized medicine, and more. Given the financial potential of the cell type, it is important to have strategies for accessing key individuals, events, and iPSC facilities.
Continue reading Do You Know the Top 5 iPS Cell Influencers (Right Now)?
In the past year, Japan has accelerated its position as a hub for regenerative medicine research, largely driven by support from Prime Minister Shinzo Abe who has identified regenerative medicine and cellular therapy as key to the Japan’s strategy to drive economic growth. The Prime Minister has encouraged a growing range of collaborations between private industry and academic partners through an innovative legal framework approved last fall. He has also initiated campaigns to drive technological advances in drugs and devices by connecting private companies with public funding sources. The result has been to drive progress in both basic and applied research involving induced pluripotent stem cells (iPS cells) and related stem cell technologies.
What is a Diversified Biobank vs. a Stem Cell Biobank?
A biobank is a type of biological repository that stores biological samples (usually human) for use in research and medicine. The registration of each sample entering and exiting the system is centrally stored on a computer system that is frequently backed up, and the physical location of each sample is noted to allow efficient location of specimens. Storage of the specimens may range from controlled ambient (room temperature), to +4°C, -20°C, -80°C, and -196°C (liquid or vapor nitrogen, LN2).
In this post, we explore seven momentous partnerships that have been formed for purposes of strengthening company dominance within the induced pluripotent stem cell (iPSC) marketplace. As you’ll discover, a major theme among the “power players” within the iPSC marketplace is non-exclusive agreements with iPS Academia Japan. These non-exclusive agreements allow companies access to an absolutely critical iPSC patent portfolio by granting access to the patented discoveries of Dr. Shinya Yamanaka, the scientist who invented induced pluripotent stem cells in 2006.
Induced pluripotent stem cells (iPSCs) represent a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. While this trial has since been paused due to safety concerns, it represents a major milestone in clinical progress with iPSCs.
In another recent event that reverberated throughout the stem cell research community, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued February 2015.
Indeed, every month there are major events occurring in the iPSC sector that shift industry dynamics. Read on to get informed about the most important iPSC market events that occurred in July of 2015. Continue reading Induced Pluripotent Stem Cell News Round-Up | July 2015
Purpose of Induced Pluripotent Stem Cell (iPSC) Marketing Analysis
An important area to consider for purposes of quantifying and assessing conditions within the iPSC market is marketing costs.
Because Google now controls over 70% of online searches, Google Adwords is the single best resource available for analyzing both marketing costs and online search behavior within the induced pluripotent stem cell (iPSC) market. Specifically, this post considers marketing costs for search terms related to iPSCs, using the Google Adwords tool.
Continue reading Price-per-Click Costs Reveal Current Levels of Market Competition for iPS Cells
Since iPSCs were first produced in 2006 from mouse cells and in 2007 from human cells, research scientists have recognized the wide-ranging potential of the cell type, including the possibility of using them in drug and toxicology screening, disease modeling, and cellular therapy applications ranging from gene correction, to whole tissue regeneration, individualized medicine, and more.
Since the discovery of induced pluripotent stem cells, the commercial sector has also recognized the huge profits that could potentially be generated from the cell type, and the question being explored among the private sector has been how to generate maximal commercial value through the development of iPSC applications and technologies.
Cord Blood SWOT Analysis Examines “Strengths, Weaknesses, Opportunities, and Threats”
A SWOT analysis is a well-established method of evaluating strengths, weaknesses, opportunities, and threats within an industry. Claim this exclusive SWOT analysis to get informed about cord blood industry conditions worldwide, including new trends that will affect your business in 2015-16.